A Study to Assess the Safety and Tolerability of ZX008 in Children and Young Adults With Dravet Syndrome or Lennox Gastaut Syndrome Currently Taking Cannabidiol

NCT03467113 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

9

Enrollment

INDUSTRY

Sponsor class

Conditions

Dravet Syndrome
Lennox Gastaut Syndrome

Interventions

DRUG: ZX008 0.2 to 0.8 mg/kg/day
DRUG: Cannabidiol

Sponsor

Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.